Worldwide Alzheimer's Disease Neuroimaging Initiative
Abstract
The Alzheimer's Disease Neuroimaging Initiative (ADNI) was launched in 2003 to speed drug development by validating imaging and blood/cerebrospinal fluid biomarkers for Alzheimer's disease clinical treatment trials. ADNI is a naturalistic (nontreatment) multisite longitudinal study. A true public–private partnership, the first phase of ADNI (ADNI 1) set a new standard for data sharing without embargo. In addition, it has been extended to 2017 by additional funding (North American‐ADNI Grand Opportunities and ADNI 2) as well as multiple projects around the world, collectively known as Worldwide ADNI (WW‐ADNI). The goal of WW‐ADNI is to harmonize projects and results across different geographical sites and to encourage and harmonize data management and availability to investigators around the world. WW‐ADNI projects are currently underway in North America, Europe, Japan, Australia, Korea, Taiwan, and Argentina, with a nascent program in China and a possible future program in Brazil.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 01, 2012
- Source ID
- 10.1016/j.jalz.2012.04.007
Entities
People
- Giovanni B. Frisoni
- Lisa J. Bain
- Maria C. Carrillo
- Michael W. Weiner
Organizations
- Alzheimer's Association
- National Institute on Aging
- National Institutes of Health
- Ngee Ann Polytechnic
- University of California, San Francisco
- Veterans Health Administration